TITLE

Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status

AUTHOR(S)
Whigham, L. D.; Dhurandhar, N. V.; Rahko, P. S.; Atkinson, R. L.
PUB. DATE
May 2007
SOURCE
International Journal of Obesity;May2007, Vol. 31 Issue 5, p850
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background:Obesity treatment with single drugs produces weight losses of about 8–10% of initial body weight. Few studies of combinations of drugs for treating obesity have been published. The combination of phentermine, an adrenergic agent, and fenfluramine, a serotonergic agent, (phen–fen) produced weight losses of about 15% of initial body weight. Fenfluramine is no longer available because it was associated with cardiac valve lesions. Phentermine–fluoxetine (phen–flu) has been proposed as an alternative for phen–fen.Objective:To compare the efficacy of treatment and prevalence of cardiac valve abnormalities on phen–flu vs phen–fen.Design:Retrospective chart review of all patients treated for at least 3 months with phen–flu (N=97) to a random sample of patients treated with phen–fen (N=98) in the Clinical Nutrition Clinic at the University of Wisconsin. Comparison of echocardiograms in all patients treated solely with phen–flu (N=21) to a random sample of patients treated with phen–fen (N=47), and to a group of subjects never treated with obesity drugs (N=26).Results:With last observation carried forward analysis (LOCF), at 6 months of treatment the phen–fen patients lost 12.6±0.6% of baseline weight and phen–flu patients lost 9.0±0.6% (P<0.001). With completers analysis, there were no significant differences in weight loss as a percent of baseline weight at 6 months (14.4±0.6 vs 13.3±0.9%). LOCF decreases in body mass index (BMI) at 6 months were −5.3 and −3.6 kg/m2 for phen–fen and phen–flu, respectively (P<0.001), and 6.2±0.3 vs 5.4±0.4 kg/m2, respectively, for the completers analysis (P – NS). Dropout rate at 6 months was higher in phen–flu subjects (44 vs 28%). In subjects without atherosclerosis of valves (presumably pre-existing), cardiac valve lesions occurred in eight of 38 phen–fen subjects and in none of 15 phen–flu subjects or 25 control subjects who had not been treated with drugs.Conclusions:The combination of phentermine and fluoxetine was not as effective as phen–fen, but was not associated with cardiac valve lesions. Longer term, larger scale studies of phen–flu are warranted.International Journal of Obesity (2007) 31, 850–857. doi:10.1038/sj.ijo.0803498; published online 5 December 2006
ACCESSION #
24943653

 

Related Articles

  • Initial weight loss as a predictor of response to obesity drugs. Dhurandhar, N V; Blank, R C; Schumacher, D; Atkinson, R L // International Journal of Obesity & Related Metabolic Disorders;Dec1999, Vol. 23 Issue 12, p1333 

    BACKGROUND: Initial weight loss has been used as a predictor of long-term response to obesity drugs. Discontinuation of drugs has been recommended if weight loss is not ≥ 1.81 kg (4 Ib) in the first month of treatment. OBJECTIVE: We compared the weight loss response at 6 months of patients...

  • Tracking the `fenphen' drug trend.  // Physician & Sportsmedicine;Sep96, Vol. 24 Issue 9, p17 

    Reports on the popularity of the drugs fenfluramine and phentermine for weight reduction and appetite suppression. Mechanism by which both drugs promote weight loss; Prescription dosages of both drugs; Method by which physicians arrive at a decision to five the fenfluramine-phentermine...

  • GPs should join debate on potential risk versus reward of obesity drug. Castaneda, Reynald // New Zealand Doctor;10/8/2014, p14 

    The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.

  • Fenfluramine and phentermine added to list of causes of valvular heart disease. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;03/25/98, Vol. 11 Issue 3, p26 

    Reports on the combined use of fenfluramine and phentermine as an added cause to valvular heart disease. Incidence and reversibility of valvular disease; List of iatrogenic causes of valvular heart disease; Chordal rupture and valvular incompetence as a possible result of myocardial biopsy.

  • Groups argue significance of 'fen-phen' study.  // Modern Medicine;Aug97, Vol. 65 Issue 8, p4 

    Reports on reactions to a study which will be published in the `New England Journal of Medicine' which found that women who were taking fenfluramine and phentermine developed valvular problems. Food & Drug Administration's issuance of an alert to physicians to check patients taking the...

  • Heart-valve disease linked to common diet drug. Brown, C. J. // CMAJ: Canadian Medical Association Journal;08/15/97, Vol. 157 Issue 4, p362 

    Describes a study to be published in the New England Journal of Medicine which observed serious heart-valve damage in patients treated for obesity with fenfluramine and phentermine (fen-phen). Research at Mayo Clinic, Rochester, Minnesota; Details of study; Drugs' effect on circulating...

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Pulmonary Hypertension Associated with Use of Phentermine. Woo-Dae Bang; Ji-Ye Kim; Hee-Tae Yu; Sung-Soo Cho; Ji-Yong Jang; Chang-Myung Oh; Boyoung Joung; Hyuk-Jae Chang // Yonsei Medical Journal;11/1/2010, Vol. 51 Issue 6, p971 

    Weight-control drugs (known as anorexigens) such as fenfluramine have been linked with pulmonary hypertension in previous reports. In our case, a 29 year old woman was admitted for shortness of breath and was diagnosed with pulmonary hypertension. Three months ago, she had been taking...

  • Cost-Effectiveness Analysis of Qsymia for Weight Loss. Finkelstein, Eric; Kruger, Eliza; Karnawat, Sunil // PharmacoEconomics;Jul2015, Vol. 33 Issue 7, p699 

    Background: Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored. Objective: To quantify the incremental cost-effectiveness of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics